https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-ind-approval-of-jk07-phase-i-study-in-china/ 2020-10-27T16:49:41+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-265m-investment-from-the-carlyle-group-to-further-innovative-rd/ 2020-10-27T16:54:23+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-announces-ind-approval-by-fda-of-jk07-phase-i-study-in-the-us/ 2020-10-27T16:56:30+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-investment-of-10m-in-viracta-therapeutics-san-diego-usa-to-support-development-of-their-kick-and-kill-combination-cancer-therapy-2/ 2020-10-27T16:57:25+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-investment-of-20m-in-medalliance-sa-nyon-switzerland-to-support-development-of-their-novel-sirolimus-coated-balloon-for-coronary-and-p/ 2020-10-27T16:57:56+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-investment-of-8m-in-mercator-medsystems-emeryville-usa-to-support-development-of-their-novel-microinjection-platform-technology/ 2020-10-27T16:58:24+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-investment-of-5m-in-go-therapeutics-cambridge-usa-to-support-development-of-their-novel-microinjection-platform-technology/ 2020-10-27T16:58:51+00:00 https://salubrisbio.eigercreative.co.uk/newsitem/salubrisbio-parent-company-salubris-pharmaceuticals-announces-investment-of-10m-in-viracta-therapeutics-san-diego-usa-to-support-development-of-their-kick-and-kill-combination-cancer-therapy/ 2020-11-06T16:14:29+00:00